<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651245</url>
  </required_header>
  <id_info>
    <org_study_id>EUMAP-2018</org_study_id>
    <nct_id>NCT03651245</nct_id>
  </id_info>
  <brief_title>European Alpha-Mannosidosis Participant</brief_title>
  <acronym>EUMAP</acronym>
  <official_title>European Alpha-Mannosidosis Participant: An International, Multicenter, Epidemiological Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal monitoring study to investigate the
      prevalence of Alpha-Mannosidosis in participants at risk for Alpha-Mannosidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha-Mannosidosis is a lysosomal storage disorder of the Glycoprotein family of diseases and
      is closely related to Mucopolysaccharidoses.It is a rare inherited disorder that causes
      problems in many organs and tissues of the body. Affected individuals may have intellectual
      disability, distinctive facial features, and skeletal abnormalities. Characteristic facial
      features can include a large head, prominent forehead, low hairline, rounded eyebrows, large
      ears, flattened bridge of the nose, protruding jaw, widely spaced teeth, overgrown gums, and
      large tongue. The skeletal abnormalities that can occur in this disorder include reduced bone
      density (osteopenia), thickening of the bones at the top of the skull (calvaria),
      deformations of the bones in the spine (vertebrae), bowed legs or knock knees, and
      deterioration of the bones and joints.

      Affected individuals may also experience difficulty in coordinating movements (ataxia);
      muscle weakness (myopathy); delay in developing motor skills such as sitting and walking;
      speech impairments; increased risk of infections; enlargement of the liver and spleen
      (hepatosplenomegaly); a buildup of fluid in the brain (hydrocephalus); hearing loss; and a
      clouding of the lens of the eye (cataract).

      Alpha-Mannosidosis is estimated to occur in approximately 1 in 500,000 people worldwide.
      Mutations in the MAN2B1 gene cause Alpha-Mannosidosis. This gene provides instructions for
      making the enzyme alpha-mannosidase. Mutations in the MAN2B1 gene interfere with the ability
      of the alpha-mannosidase enzyme to perform its role in breaking down mannose-containing
      oligosaccharides. These oligosaccharides accumulate in the lysosomes and cause cells to
      malfunction and eventually die. Tissues and organs are damaged by the abnormal accumulation
      of oligosaccharides and the resulting cell death, leading to the characteristic features of
      Alpha-Mannosidosis.

      Modern methods, as DBS based mass-spectrometry give a great opportunity to

        -  Simplify the diagnostic process

        -  Simplify the logistics

        -  Increases stability and reproducibility

        -  Characterize specific metabolic alterations in the blood of affected patients that allow
           diagnosing the disease earlier, with a higher sensitivity and specificity.

      A more specific diagnosis that permits earlier detection of the disease, as well as
      assessment of the disease activity and progression, would also permit improved chances for
      earlier treatment of those patients suffering from the disease.

      It is the goal of this international, multicentre, epidemiological study to explore and
      analyse the prevalence of Alpha-Mannosidosis disease in a cohort of 1.000 patients with a
      suspicion of Alpha-Mannosidosis disease, based on the patient's clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epidemiological analysis of the prevalence of Alpha-Mannosidosis disease in a cohort of patients with suspicion for Alpha-Mannosidosis, based on their clinical symptoms.</measure>
    <time_frame>3 years</time_frame>
    <description>Number of identified Alpha-Mannosidosis patients, showing a mutation/pathogenic variant in the MAN2B1-Gene, within a cohort of 1000 suspected cases using respective patient's dry-blood sample for confirmatory genetic testing (NGS-based sequencing of MAN2B1-gene)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishment of biomarker/s in MAN2B1 positive cohort.</measure>
    <time_frame>3 years</time_frame>
    <description>Alpha-Mannosidosis-positive samples will be validated for the identification of potential biomarkers (based on MS/MS-Tandem spectroscopy) and compared with the merged control samples in order establish a disease-specific biomarker.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Immunodeficiency</condition>
  <condition>Skeletal Abnormalities</condition>
  <condition>Deafness</condition>
  <condition>Mental Retardation</condition>
  <condition>Gingival Hypertrophy</condition>
  <condition>Facial Dysmorphism</condition>
  <arm_group>
    <arm_group_label>Participants with suspicion for Alpha-Mannosidosis</arm_group_label>
    <description>Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants at risk for Alpha-Mannosidosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant's parent/legal guardian

          -  The participant is aged between 2 months and 18 years of age

          -  The participant has a family history of Alpha-Mannosidosis or is at risk for
             Alpha-Mannosidosis according to one or more of the following symptoms: recurrent
             infections, skeletal abnormalities, hearing impairment-deafness, progressive
             neurological symptoms, impairment of mental functions, gingival hypertrophy,
             dysmorphic facial features, motoric disturbances of no obvious etiology

        Exclusion Criteria:

          -  Informed consent is not provided by the partici-pant's parent/legal guardian

          -  The participant is younger than 2 months or older than 18 years

          -  The participant has no family history of Alpha-Mannosidosis and is not at risk for
             Alpha-Mannosidosis (represents none of the following symptoms): recurrent infections,
             skeletal abnormalities, hearing impairment-deafness, progressive neurological
             symptoms, impairment of mental functions, gingival hypertrophy, dysmorphic facial
             features, motoric disturbances of no obvious etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Zielke</last_name>
    <phone>+49 (0)38180113667</phone>
    <email>Susanne.Zielke@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Häusler, MD</last_name>
      <phone>+49 (0)241800</phone>
      <email>mhaeusler@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ute Deutz, MD</last_name>
      <phone>+49 (0)241800</phone>
      <email>udeutz@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Häusler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Leitung Sozialpädiatrisches Zentrum, Klinik für Pädiatrie m.S. Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Kaindl, MD</last_name>
      <phone>+49 (0)30450566301</phone>
      <email>angela.kaindl@charite.de</email>
    </contact>
    <investigator>
      <last_name>Angela Kaindl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhruniversität Bochum im St. Josef Hospital, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Lücke, MD</last_name>
      <phone>+49 (0)2345092611</phone>
      <email>thomas.luecke@klinikum-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Lücke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus GmbH, Sozialpädiatrisches Zentrum</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Christof Schwabe, MD</last_name>
      <phone>+49 (0)355463159</phone>
      <email>spz@ctk.de</email>
    </contact>
    <investigator>
      <last_name>Georg Christof Schwabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus GmbH, Klinik für Kinder und Jugendmedizin</name>
      <address>
        <city>Cottbus</city>
        <zip>03049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Stolz, MD</last_name>
      <phone>+49 (0)355462336</phone>
      <email>kinderklinik@ctk.de</email>
    </contact>
    <investigator>
      <last_name>Simone Stolz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hals-Nasen und Ohrenheilkunde</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Arweiler-Harbeck, MD</last_name>
      <phone>+49 (0)2017232386</phone>
      <email>Diana.Arweiler-Harbeck@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Diana Arweiler-Harbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen, Zentrum für Kinderheilkunde und Jugendmedizin, Abteilung für Kinderneurologie, Sozialpädiatrie und Epileptologie</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hahn, MD</last_name>
      <phone>+49 (0)64198558742</phone>
      <email>andreas.hahn@paediat.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle Universitätsklinik und Poliklinik für Pädiatrie I</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Stange, MD</last_name>
      <phone>+49 (0)3455572388</phone>
      <email>marcus.stange@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Stange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKE - Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Sophie Hoffmann, MD</last_name>
      <phone>+49 (0)40741022903</phone>
      <email>as.hoffmann@uke.de</email>
    </contact>
    <investigator>
      <last_name>Anna Sophie Hoffmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Deutsches HörZentrum Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Lesinski-Schiedat, MD</last_name>
      <phone>+49 (0)5115326565</phone>
      <email>dhz.info@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Anke Lesinski-Schiedat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Hals-, Nasen- und Ohrenheilkunde</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Guntinas Lichius, MD</last_name>
      <phone>+49 (0)36419329301</phone>
      <email>orlando.guntinas@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Orlando Guntinas Lichius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Neuropädiatrie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Husain, MD</last_name>
      <phone>+49 (0)36419329685</phone>
      <email>ralf.husain@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Husain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNIVERSITÄTSKLINIKUM LEIPZIG AöR, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Dietz, MD</last_name>
      <phone>+49 (0)3419721700</phone>
      <email>Dietz_Studien@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Dietz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Mülheim, Sozialpädiatrisches Zentrum,</name>
      <address>
        <city>Mülheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Busse, MD</last_name>
      <phone>+49 (0)2088811390</phone>
      <email>Melanie.Busse@eko.de</email>
    </contact>
    <investigator>
      <last_name>Melanie Busse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sozialpädiatrisches Zentrum der HTZ Neuwied gGmbH</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Krahn Peper, MD</last_name>
      <phone>+49 (0)26319656225</phone>
      <email>claudia.krahn-peper@htz-neuwied.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Krahn Peper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Oberhausen, Sozialpädiatrisches Zentrum</name>
      <address>
        <city>Oberhausen</city>
        <zip>46047</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Opp, MD</last_name>
      <phone>+49 (0)2088812300</phone>
      <email>Joachim.Opp@eko.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Opp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elblandkliniken Stiftung &amp; Co. KG - Elblandklinkum Riesa Sozialpädiatrisches Zentrum und Frühförderstelle</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hildebrandt, MD</last_name>
      <phone>+49 (0)3525755100</phone>
      <email>martin.hildebrandt@elblandkliniken.de</email>
    </contact>
    <investigator>
      <last_name>Martin Hildebrandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder-und Jungendmedizin des Universitätsklinikums Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kraemer, MD</last_name>
      <phone>+49 (0)73150057010</phone>
      <email>johannes.kraemer@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Kraemer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinder und Jugendliche Sozialpädiatrisches Zentrum (SPZ) im Marien-Hospital</name>
      <address>
        <city>Wesel</city>
        <zip>46483</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Schulze-Frenking, MD</last_name>
      <phone>+49 (0)28110460710</phone>
      <email>spz.mhw@prohomine.de</email>
    </contact>
    <investigator>
      <last_name>Gudrun Schulze-Frenking, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HNO-Universitätsklinik, Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gürtler, MD</last_name>
      <phone>+41 (0)612654101</phone>
      <email>nicolas.guertler@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Gürtler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern Universitätsklinik für Neurologie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hoepner, MD</last_name>
      <phone>+41 (0)316640067</phone>
      <email>robert.hoepner@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Robert Hoepner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alpha-Mannosidosis disease</keyword>
  <keyword>prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Hypertrophy</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

